Catalog No.
FHD06910
Species reactivity
Human
Host species
Mouse
Isotype
IgG1, kappa
Clonality
Monoclonal
Conjugation
Unconjugated
Target
IL-2R subunit beta, Interleukin-15 receptor subunit beta, IL2RB, IL-2 receptor subunit beta, CD122, High affinity IL-2 receptor subunit beta, p75, Interleukin-2 receptor subunit beta, IL-2RB, p70-75, IL15RB
Concentration
1.38 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P14784
Applications
FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
MikB1
Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice., PMID:40139833
Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies., PMID:40132909
Characterization of anti-asialo-GM1 monoclonal antibody., PMID:39693935
IL-2/anti-IL-2 antibody complexes augment immune responses to therapeutic cancer vaccines., PMID:39556726
Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing., PMID:39381601
CD122 is an activation marker ensuring proper proliferation of T cells in teleost., PMID:39153581
IL-15/IL-15Rα-Fc-Fusion Protein XmAb24306 Potentiates Activity of CD3 Bispecific Antibodies through Enhancing T-Cell Expansion., PMID:38739434
Efbalropendekin Alfa enhances human natural killer cell cytotoxicity against tumor cell lines in vitro., PMID:38515757
rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors., PMID:38471713
Blockade of CD122 on memory T cells in the skin suppresses sclerodermatous graft-versus-host disease., PMID:36966029
Anti-CD122 antibody restores specific CD8+ T cell response in nonalcoholic steatohepatitis and prevents hepatocellular carcinoma growth., PMID:36891258
Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial., PMID:36823323
IL-15 induced bystander activation of CD8+ T cells may mediate endothelium injury through NKG2D in Hantaan virus infection., PMID:36590594
PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program., PMID:36171288
In vitro-induced Foxp3+ CD8+ regulatory T cells suppress allergic IgE response in the gut., PMID:36000308
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma., PMID:35710741
Juzentaihoto Exerts Anti-Allergic Effects by Inhibiting Effector T-Cell Activation and Inducing and/or Activating Regulatory T Cells in a Murine Model of Contact Hypersensitivity., PMID:34818253
FLT3L Release by Natural Killer Cells Enhances Response to Radioimmunotherapy in Preclinical Models of HNSCC., PMID:34518311
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma., PMID:34255535
A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells., PMID:34011961
IL-2Rβγ signalling in lymphocytes promotes systemic inflammation and reduces plasma cholesterol in atherosclerotic mice., PMID:33945906
CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation., PMID:33849925
A novel immune prognostic index for stratification of high-risk patients with early breast cancer., PMID:33420250
An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer., PMID:33353953
Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species., PMID:33328333
Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab., PMID:33298619
CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade., PMID:32948605
CD122-targetted IL-2 signals cause acute and selective apoptosis of B cells in Peyer's Patches., PMID:32728053
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design., PMID:32723187
A Method of Assessment of Human Natural Killer Cell Phenotype and Function in Whole Blood., PMID:32508837
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)., PMID:32439653
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy., PMID:32005826
Natural Killer Cells Promote Kidney Graft Rejection Independently of Cyclosporine A Therapy., PMID:31616441
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control., PMID:31462678
Clinical trial of a humanized anti-IL-2/IL-15 receptor β chain in HAM/TSP., PMID:31402625
Natural killer T cell activation increases iNOS+CD206- M1 macrophage and controls the growth of solid tumor., PMID:31387637
Interleukin-27 promotes CD8+ T cell reconstitution following antibody-mediated lymphoablation., PMID:30944247
CD4+ TSCMs in the Bone Marrow Assist in Maturation of Antibodies against Influenza in Mice., PMID:30733641
Development of a novel class of interleukin-2 immunotherapies for metastatic cancer., PMID:30673115
Stage-specific requirement of kinase PDK1 for NK cells development and activation., PMID:30622306
Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo., PMID:30021889
Revisiting IL-2: Biology and therapeutic prospects., PMID:29980618
CD122 blockade restores immunological tolerance in autoimmune type 1 diabetes via multiple mechanisms., PMID:29367461
Targeting of CD122 enhances antitumor immunity by altering the tumor immune environment., PMID:29312597
The ERM Protein Moesin Regulates CD8+ Regulatory T Cell Homeostasis and Self-Tolerance., PMID:28978692
Suppression of allograft rejection by CD8+CD122+PD-1+ Tregs is dictated by their Fas ligand-initiated killing of effector T cells versus Fas-mediated own apoptosis., PMID:28445940
Novel model of double transgenic mouse results in autoimmune diabetes in males., PMID:27683954
A Simple, Rapid, and Highly Sensitive Electrochemical DNA Sensor for the Detection of α- and β-Thalassemia in China., PMID:27228385
The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade., PMID:27082453
Donor-antigen Inoculation in the Testis Promotes Skin Allograft Acceptance Induced by Conventional Costimulatory Blockade via Induction of CD8 + CD122+ and CD4 + CD25+ Regulatory T Cells., PMID:26569069
For research use only. Not for human or drug use.
